Onder Demir-Onder

Dr. Onder Demir-Onder


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 August 2021 in TURKISH JOURNAL OF MEDICAL SCIENCES
Verified
Journal Article
Closed access
TYTuğba YANIK YALÇIN
Tuğba YANIK YALÇIN
ÖAÖzlem Azap
Özlem Azap
Adem KoseAdem Kose
Adem Kose
YBYasar Bayindir
Yasar Bayindir
ESElif Mukime Saricaoglu
Elif Mukime Saricaoglu
MHMehmet Haberal
Mehmet Haberal
Background/aim: The aim of this study is to evaluate the distribution, sources, clinical features, and mortality rates of bacteremia due to evaluation of extensively drug-resistant (XDR) gram negative among solid-organ transplant (SOT) recipients. Materials and methods: A retrospective study of SOT recipients with bacteremia due to XDR gram-negative pathogens in 11 centers between 2016 and 2018 was conducted. Patients' records were evaluated. Results: Of 171 bacteremia that occurred in 164 SOT recipients, 93 (56.7%) were liver, 46 (28%) kidney, 14 (8.5%) heart, and 11 (6.7%) lung recipients. Bacteremia episodes were recorded in the first year in 63.7% of the patients (n = 109), early-onset bacteremia was recorded in 45% (n = 77) of the episodes. In multivariate analysis, catheter-associated bacteremia was an independent risk factor for 7-day mortality (p = 0.037), and early-onset bacteremia was found as an independent risk factor for 30-day mortality (p = 0.017). Conclusion: Difficult-to-treat infections due to XDR bacteria in SOT recipients shadow the success of transplantation. Central venous catheters seem to be the main risk factor. Judicious use of medical devices is of pivotal importance.

29 December 2023 in Infectious Diseases and Clinical Microbiology
Verified
Journal Article
Open access
MDMustafa Deniz
Mustafa Deniz
ODOnder Demir-Onder
Onder Demir-Onder
YÖYusuf Özkaraman
Yusuf Özkaraman
ZAZafer Adıgüzel
Zafer Adıgüzel
KBKadir Balaban
Kadir Balaban
Eosinophilic cellulitis (EC) is a rare inflammatory skin condition with fewer than 200 documented cases in the medical literature. There are only a limited number of case reports available from our country. The prevalence and incidence of EC are unknown. The disease is characterized by pruritic, non-purulent, erythematous plaques (...)

13 December 2021 in TURKISH JOURNAL OF MEDICAL SCIENCES
Verified
Journal Article
Open access
ODOnder Demir-Onder
Onder Demir-Onder
AKAyşegül SEREMET KESKİN
Ayşegül SEREMET KESKİN
HANDE BERKHANDE BERK
HANDE BERK
DSDerya Seyman
Derya Seyman
NÖNefise Öztoprak
Nefise Öztoprak
Background/aim: As the experience has increased regarding SARS-CoV-2 in time, treatment trends have changed since the beginning of the pandemic. This study aimed to compare the outcomes of different treatment modalities for inpatients in a tertiary pandemic Materials and methods: Individuals aged 18 years and above who tested positive for SARS-CoV-2 in PCR with presenting COVIDrelated radiological findings, hospitalized for at least 3 days, and completed follow-up between March 15, 2020 and November 30, 2020 were included in the study. Patients' data were reviewed retrospectively. Seven treatment groups based on the single or combined use of hydroxychloroquine, oseltamivir, favipiravir, and remdesivir were formed and compared in terms of mortality, survival, length of hospital stay, need for intensive care, and mechanical ventilation. Results: A total of 321 patients were included in the study. The length of hospital stay, the need for intensive care, and mechanical ventilation were lower in Group 1 (hydroxychloroquine) and Group 2 (hydroxychloroquine + oseltamivir) compared to the other groups (p < 0.05). No significant difference was determined in survival between treatment groups. Analysis of prognostic factors affecting overall survival revealed that the need for intensive care and mechanical ventilation increased mortality [11.1 times (p < 0.001) and 6.48 times (p < 0.001), respectively]. Conclusion: No significant difference was determined between different treatment protocols in terms of their impact on survival. To end the COVID-19 pandemic, there is an urgent need to develop highly efficient, rapid-acting, and orally available antiviral drugs.

27 March 2025 in Infectious Diseases and Clinical Microbiology
Verified
Journal Article
Open access
PİPelin İrkören
Pelin İrkören
EBElif Aguloglu Bali
Elif Aguloglu Bali
OUOguz Usta
Oguz Usta
ASArzu Senol
Arzu Senol
BMBaris Manavli
Baris Manavli
Onder ErgonulOnder Ergonul
Onder Ergonul
The residency program of infectious diseases and clinical microbiology (IDCM) in Türkiye was started in 1983 by adopting the name IDCM. The IDCM program in Türkiye is a five-year program, including related clinical rotations. Presenting a thesis at the end of this program is mandatory. The first specialty thesis in the field of IDCM was

28 August 2022 in International Journal Of Clinical Practice
Verified
Journal Article
Open access
PDF file
AKAyşegül Seremet Keski̇n
Ayşegül Seremet Keski̇n
DSDerya Seyman
Derya Seyman
ODOnder Demir-Onder
Onder Demir-Onder
FKFiliz Kizilateş
Filiz Kizilateş
OKOlgun Keski̇n
Olgun Keski̇n
Introduction and Objectives. The comparative efficacy of colistin with a loading dose (LD) and without LD remains unknown. We aimed at assessing the efficacy and safety of colistin with LD in patients with multidrug resistance (MDR) Acinetobacter baumannii ventilator‐associated pneumonia (VAP) or pneumonia, compared with colistin without LD. Materials and Methods. Adult patients administered colistin with and without LD for MDR Acinetobacter baumannii VAP/pneumonia in intensive care units (ICUs) in a tertiary teaching hospital between 1 January 2018 and 31 December 2019 were included in this retrospective cohort study. The primary endpoint was an assessment of clinical and microbiological success between treatment groups. Secondary endpoints included 14‐ and 30‐day mortality and development of nephrotoxicity. Results. A total of 101 patients were included (colistin with LD, n = 57; colistin without LD, n = 44). No significant difference in clinical success was observed between groups (73.7% versus 77.3%; p = 0.670). In patients receiving colistin with LD, the microbiological success rate increased from 65.9% to 71.9%, but there was no statistically significantly difference (p = 0.510). In terms of using combination therapies with carbapeneme and/or tigecycline, there was no significant difference between treatment groups (p = 0.30). The rates of 14‐ and 30‐day mortality were similar between groups. The colistin with LD group had a higher rate of nephrotoxicity compared to the other group (52.6% versus 20.5% p = 0.001). The clinical and microbiological response times were found significantly higher in the colistin with LD group (p = 0.001; p = 0.017). Conclusion. Colistin with LD was associated with a higher risk of nephrotoxicity and was not related to clinical success, microbiological success, and prolonged survival. Randomized comparative studies are needed to confirm the efficacy of LD colistin regimen on MDR Acinetobacter infection.

30 October 2020 in Bezmialem Science
Verified
Journal Article
Closed access
ASAyşegül KESKİN SEREMET
Ayşegül KESKİN SEREMET
FKFiliz Kizilateş
Filiz Kizilateş
ODOnder Demir-Onder
Onder Demir-Onder
NÖNefise Öztoprak
Nefise Öztoprak